Information  X 
Enter a valid email address

Grupo Clarin S.A. (GCLA)

  Print      Mail a friend

Wednesday 08 May, 2019

Grupo Clarin S.A.

Appointment of Company Authorities

RNS Number : 4237Y
Grupo Clarin S.A.
08 May 2019
 

 

Grupo Clarín appoints Company Authorities for the period 2019

 

On May 7, 2019, Grupo Clarín S.A. (the "Company") informed to the Argentine Securities Commission and the Buenos Aires Stock Exchange, the authorities appointed by the Board of Directors at the Annual Ordinary Shareholders' Meeting held on April 30, 2019.

 

President:

Jorge Carlos Rendo

 

Vicepresident:

Héctor Mario Aranda

 

Members of the Board of Directors

Felipe Noble Herrera, Alma Rocío Aranda, Horacio Ezequiel Magnetto, Francisco Pagliaro, Lorenzo Calcagno, Andrés Gabriel Riportella, Horacio Eduardo Quirós and Ignacio Rolando Driollet.

 

Alternate Members of the Board of Directors

Francisco Iván Acevedo, Martín Gonzalo Etchevers, Patricia Miriam Colugio, Eloisa Prieri Belmonte, Eugenio Eduardo Sosa Mendoza, Marcelo Fernando Boncagni, Carlos Rebay, Luis Germán Fernández, Lucas Puente Solari and Alfredo Enrique Kahrs.           

 

In addittion, the Audit Committee approved the appointment of its members, composed as follows:

 

President:

Lorenzo Calcagno

 

Vicepresident:

Andrés Riportella

 

Head member:

Héctor Mario Aranda

 

Alternate members:

Francisco Iván Acevedo, Carlos Rebay and Luis Germán Fernández.

 

 

 

Enquiries:

 

In Buenos Aires:

Agustín Medina Manson

Grupo Clarín

Tel: +5411 4309 7215

Email: [email protected] 

 

In London:

Alex Money

Jasford IR

Tel: +44 20 3289 5300

Email: [email protected] 

 

In New York:

Melanie Carpenter

I-advize Corporate Communications

Tel: +1 212 406 3692

Email: [email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAUWSVRKNAVRAR

a d v e r t i s e m e n t